Chromosomal DNA of different species of mycobacteria, Mycobacterium tuberculosis, Mycobacterium leprae, Mycobacterium avium and Mycobacterium smegmatis, has been submitted to polymerase chain reaction using two oligonucleotide primers highly homologous to DNA sequences flanking the quinolone resistance-determining region in the gyrA gene of Escherichia coli and Staphylococcus aureus. For each of these mycobacterial species, a 150-bp DNA fragment hybridizing with an intragenic probe of the gyrA gene of E. coli K12 was obtained. The nucleotide sequences of the 108-bp fragments amplified from M. tuberculosis and M. aviurn were determined. The two sequences were 87% homologous. Except for one residue, their deduced amino acid sequences were identical and shared 67% homology with the quinolone resistance-determining region of the gyrase A subunits of E. coli and S. aureus. Sequencing of the 108-bp fragment amplified from an in vitro mutant of M. avium, highly resistant to fluoroquinolones, showed a point mutation leading to the substitution of Ala for Val at a position corresponding to residues involved in quinolone resistance in E. coli and S. aureus, i.e. Ser 83 for E. coli and Ser 84 for S. aureus.
Introduction
Fluoroquinolones are recently developed drugs active against mycobacteria, especially Mycobacterium leprae and Mycobacterium tuberculosis [1] [2] [3] . They are used for the treatment of leprosy and in cases of tuberculosis caused by multiple drug resistant strains [3] . Since the prevalence of such 50 bacteria other than mycobacteria, quinolone resistance is mostly related to mutations in gyrA [6] , the structural gene of the A subunit of DNA gyrase which is the intracellular target of quinolones [7] . Most of these mutations are located within a conserved region in the gyrA gene of Escherichia coli [8] [9] [10] and Staphylococcus aureus [11] . Therefore, this region is now referred to as the quinolone resistance-determining region in the gyrA gene [9] .
In order to initiate studies on quinolone resistance in mycobacteria, we have designed a DNA amplification process for the cloning of a mycobacterial DNA fragment homologous to the quinolone resistance-determining region in the gyrA gene of E. coli and S. aureus. This amplification process has been applied to DNA extracted from different mycobacterial species such as M. tuberculosis, the causative agent of tuberculosis, M. leprae, the causative agent of leprosy, M. avium which causes opportunistic infections in patients with AIDS and Mycobacterium smegmatis which is the reference species for genetic studies on mycobacteria. The nucleotide sequence of the amplified DNA was determined for two species, M. tuberculosis and M. avium. To assess that the DNA fragment obtained by PCR corresponds in mycobacteria to the quinolone resistance-determining region, the amplification and sequencing process was also applied to a mutant strain resistant to fluoroquinolones. For that purpose, and considering the high pathogenicity of M. tuberculosis, we decided to select such a mutant from a wild-type strain of M. avium.
Materials and Methods

Bacterial strains and plasmids
The strains of M. tuberculosis and M. avium were clinical isolates from Piti6 Salp~tri~re hospital. M. tuberculosis was grown on LoewensteinJensen medium, and M. avium on Mueller-Hinton agar. The M. avium mutant resistant to fluoroquinolones was obtained by a one-step selection on agar containing 32 tzg ml-1 of ofloxacin. M. leprae 90002 was isolated from a lepromatous patient from the Ivory Coast and was grown in the mice foot-pad [16] . M. smegmatis 56.5 is a reference wild-type strain obtained from Institut Pasteur, Paris, and was grown on Mueller-Hinton agar. E. coli JM101 (Clontech) is a host strain for recombinant phage vectors. Plasmid pRM386 [13] carries the gyrA gene of E. coli K12.
Prepration of DNA and nucleic acid techniques
For M. tuberculosis, M. avium and M. smegmatis, one colony (about 106 bacterial cells) was suspended in 500/zl of distilled water. DNA was extracted at room temperature from 100 Izl of this suspension, using the method described by Boom [14] : ceils were lysed in the chaotropic agent guanidium thiocyanate (GuSCN) and DNA 
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was complexed with silica particles (Sigma) in the presence of GuSCN (Fluka). After washing twice with 70% (v/v) ethanol and once with acetone, the particles were dried for 10 min at 56°C. DNA was then eluted from the silica pellet in 80/xl of distilled water (10 min at 56°C). Between 1 and 5 /zl was used for each PCR. For M. leprae, a suspension containing l0 s ceils per ml was prepared as described by Shepard [12] . DNA was extracted using the method of Woods [15] : ceils were suspended in 100 /~1 of distilled water and subjected to a series (five times) of heat/cold shocks, alternatively boiling (1 min) and snap-freezing (1 min at -80°C). Ten ~1 was used in PCR.
The oligonucleotides Pril, 2, 3 and 4 (Table 1 ) were purchased from Bioprobe Systems. Digestions with restriction endonucleases SphI and KpnI (Pharmacia), cloning experiments and electrophoresis in agarose gels were performed as described [16] .
Polymerase chain reaction (PCR)
PCR with oligonucleotides Pril, 2, 3 and 4 used as primers was carried out in a final volume of 100 ~1 containing 10/~1 of each primer (Pril + Pri2, Pri3 + Pri4, 4 ~M), 5/xl of DNA suspension used as template, 10 tzl of dNTPs (dATP, dCTP, dGTP, dq-TP, 2 mM each) and 10 /zl of Taq buffer containing 2.5 U of Taq polymerase (Boehringer). After 10 min of denaturation at 94°C, 40 amplification cycles were performed as follows: denaturation at 94°C for 1 min, annealing at 55°C for 1 min and extension at 72°C for 1 min. A final extension step was performed for 10 min at 72°C. A positive control, in which mycobacterial DNA was replaced by 50 ng of plasmid pRM386 DNA, and a negative control in which DNA was replaced by distilled water, were introduced in each run of experiments.
Sequencing of PCR-amplified DNA
The 160-bp DNA fragments obtained by PCR with Pri3 and Pri4 were purified from a 3% low-melting agarose gel using Mermaid ® kit (Bio 101). The purified DNA was digested by SphI and KpnI, ligated into M13mpl8 and M13mpl9 previously digested by the same enzymes, introduced into E. coli JM101 by transformation, and sequenced using T7 polymerase (T7 sequencing kit, Pharmacia) according to the manufacturer's recommendations. The products of the sequencing reaction were resolved by electrophoresis on 7% polyacrylamide gel as described [16] .
Nucleic acid hybridization
For Southern hybridization [16] , PCR-amplified DNA fragments resolved by electrophoresis on a 1.5% agarose gel were transferred to a nylon membrane Hybond-N ® (Amersham). A 150-bp fragment internal to the gyrA gene of E. coli K12, obtained by PCR with primers Pril and Pri2 using plasmid pRM386 as a template, was used as a probe. The probe was labelled by random priming with [a-32p]dCTP (3000 Ci mmo1-1) using the Megaprime ® kit (Amersham). Hybridization was performed overnight at 50°C in 5 x SSC (SSC is 0.15 M NaCl, 0.015 M sodium citrate), 0.7% dehydrated non-fat milk. Washes under low stringency conditions were in 2 x SSC, 0.1% SDS for 10 rain at room temperature.
Results and Discussion
Most of the mutations known to confer bacterial resistance to quinolones correspond to amino acid modifications located within a conserved region of the gyrase A subunit referred to as the quinolone resistance-determining region in E. coti and S. aureus [9, 11] . By using the alignment of the reported amino acid sequences of the gyrase A subunits of E. coli, S. aureus and Bacillus subtilis [8, 11, 17] , we have identified in this region two conserved sequences flanking a 36-residue segment which includes most of the point mutations involved in quinolone resistance in E. coli (positions 83, 84, 87 and 106) [8, 9] and in S. aureus (positions 84, 85 and 88) [11] . The two conserved sequences are located between residues 75 and 81, and between residues 118 and 124, respectively, in the numbering system used for E. coli [8] . With the aim of amplifying the mycobacterial DNA fragment corresponding to the quinolone resistance-determining region, we have assumed that the two conserved sequences we identified in the gyrase A subunits of E. coli, S. aureus and B. subtilis are also conserved in mycobacteria. On the basis of the nucleotide sequences corresponding to these amino acid sequences, we have designed two oligonucleotide primers as tools for genomic amplifications. Primer Pril (Table 1) corresponds to the sequence of the leading strand encoding the peptide segment 75 to 81, whereas primer Pri2 (Table 1) is homologous to the sequence of the lagging strand that determines the amino acid region 118 to 124 [8] . The nucleotide sequence of the two primers was optimized at the level of the third base of each codon in a way to obtain a final GC content similar (66%) to that of the mycobacterial genome [18] .
By using the two oligonucleotides Pril and Pri2, we amplified from the total DNA of M. tuberculosis or M. avium a DNA fragment of 150 bps (Fig. la) . The hybridization of these fragments with a probe specific for the sequence of the quinolone resistance-determining region in the gyrA gene of E. coli suggested that the sequences we amplified were derived from the gyrA gene (Fig. lb) . To confirm this resuIt, we cloned and sequenced the 150-bp DNA fragments obtained by PCR from M. tuberculosis and M. avium in order to compare their sequences to those of the gyrA genes of non-related bacterial species. Two successive PCRs were used prior to the cloning reaction, since we did not succeed in directly cloning PCR-products in bacteriophage M13mpl8 or mpl9. The first PCR was performed with Pril and Pri2. The resulting product was used as a template in a second PCR carried out with the primers Pri3 and Pri4 described in Table  1 . These two primers are derived from Pril and Pri2 by modifications leading to 26mer-oligonucleotides in which enzyme restriction sites SphI and KpnI have been introduced in Pri3 and Pri4, respectively (Table 1) . Thus, the second PCR was used to introduce cohesive restriction sites at each extrzmity of the amplified fragments which were then cloned into the pelylinker region of phage vectors M13mpl8 and -mp19 [16] . In order to avoid artifactual mutations due to polymerization errors by the Taq enzyme, we cloned for each mycobacterium the PCR products obtained from two independent runs of amplifications. For each PCR-product ligated into M13mpl8 and mpl9, the sequences of the three clones were determined and compared. The nucleotide sequences we obtained consisted of the sequences of primers Pri3 and Pri4 enclosing a 108-bp DNA fragment from M. tuberculosis or M. avium genome (Fig. 2) . The sequences of the 108-bp fragments from the two species shared 87% identity. Their deduced amino acid sequences, which defined in one of the three reading frames a peptide of 36 amino acid residues, were identical except for one residue, a threonine instead of a serine in the case of M. avium, at a position corresponding to 88 in gyrA of E. coli (Fig. 3) . The overall identity between nucleotide sequences from either M. tuberculosis or M. avium and the sequences reported for the gyrA genes of E. coli, S. aureus or B. subtilis was 69%, 55% and 55%, respectively (data not shown). At the amino acid level, the sequences from both mycobacterial species shared respectively 67%, 67% and 55% identity with the corresponding sequences of the gyrase A subunits of E. coli, S. aureus or B. subtilis (Fig. 3) . Thus, the 108-bp DNA fragment we amplified from M. tuberculosis and M. avium was homologous to the quinolone resistance-determining region in gyrA of E. coli and S. aureus. In order to assess that this fragment can be also associated with quinolone resistance in mycobacteria, we decided to compare the sequences obtained from a wild-type strain of M. avium with that obtained from its fluoroquinolone resistant mutant selected in vitro. The M1Cs of ofloxacin against the wild-type strain of M. avium and its mutant were 16 and 128 /xg m1-1, respectively. The comparison of the nucleotide sequences of the 108-bp fragments obtained from these two M. avium strains showed a point mutation (C to T) at the 5th nucleotide (Fig. 2) which leads to the substitution of an alanine codon for a valine codon. The codon involved in this substitution corresponded to the 83rd in E. coli gyrA, and to the 84th in S. aureus gyrA (Fig. 3) . Mutations in the codon 83 in E. coli gyrA and 84 in S. aureus gyrA are the most frequently described as a cause of acquired resistance to quinolones in E. coli [8, 9] and in S. aureus [11] . In both species, the substitutions observed are often a tryptophan or a leucine residue for a serine residue.
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Finally, the amplification process used for M. tuberculosis and M. avium was also used to amplify a 150-bp DNA fragment from the total DNA of M. leprae and M. smegmatis. The hybridization of the fragments obtained by PCR from the two latter species with the gyrA probe internal to the quinolone resistance-determining region of E. coli (Fig. lb) suggested that these fragments were also homologous to gyrA.
Therefore, these results showed (i) that we have amplified and cloned from mycobacteria DNA fragments homologous to the quinolone resistance-determining region in the gyrA gene of E. coli and S. aureus; (ii) that this region is highly conserved between mycobacteria and other species on the one hand, and between different mycobacterial species (the sequences reported here for M. tuberculosis and M. avium are almost identical) on the other hand; and (iii) that this region is associated with quinolone resistance in mycobacteria since a point mutation, which is similar to those described in E. coli and S. aureus as conferring quinolone resistance, was found in a mutant of M. avium highly resistant to fluoroquinolones. It is very likely that this region is crucial for quinolone susceptibility, since it probably encodes a part of the domain of the gyrase A subunit which interacts with quinolones [20] .
Consequently, we expect that if the acquired resistance to fluoroquinolones reported for some strains of M. tuberculos& [2] is due to mutations in gyrA, these mutations are likely to be located within the fragment of the mycobacterial genome characterized in this study. Although, to date, acquired resistance to fluoroquinolones has not been described in mycobacterial species of clinical importance other than M. tuberculosis, the amplification process described in this report could facilitate the identification and the study of the genes encoding the gyrase A subunit of any mycobacterial species.
